Clinical trials for Lennox–Gastaut syndrome: Challenges and priorities
Open Access
- 23 October 2024
- journal article
- review article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (11) , 2818-2835
Abstract
Objective: Lennox‐Gastaut syndrome (LGS) is a severe, childhood‐onset epilepsy that is typically refractory to treatment. We surveyed the current landscape of LGS treatment, aiming to identify challenges to the development of efficacious therapies, and to articulate corresponding priorities toward clinical trials that improve outcomes. Methods: The LGS Special Interest Group of the Pediatric Epilepsy Research Consortium integrated evidence from the literature and expert opinion, into a narrative review. Results: We provide an overview of approved and emerging medical, dietary, surgical and neuromodulation approaches for LGS. We note that quality of care could be improved by standardizing LGS treatment based on expert consensus and empirical data. Whereas LGS natural history is incompletely understood, prospective studies and use of large retrospective datasets to understand LGS across the lifespan would enable clinical trials that address these dynamics. Recent discoveries related to LGS pathophysiology should enable development of disease‐modifying therapies, which are currently lacking. Finally, clinical trials have focused chiefly on seizures involving “drops,” but should incorporate additional patient‐centered outcomes, using emerging measures adapted to people with LGS. Interpretation: Clinicians and researchers should enact these priorities, with the goal of patient‐centered clinical trials that are tailored to LGS pathophysiology and natural history.Keywords
Funding Information
- McKnight Foundation
- Citizens United for Research in Epilepsy
- Stanford Maternal and Child Health Research Institute
- Marinus Pharmaceuticals
- American Epilepsy Society
- Jazz Pharmaceuticals
- RTW Charitable Foundation
- Doris Duke Charitable Foundation
- Amgen
- Michigan Institute for Clinical and Health Research (K12TR004374)
- BAND foundation
- National Institutes of Health (K08NS119800, R01NS130113)
This publication has 145 references indexed in Scilit:
- Genetic testing and counseling for the unexplained epilepsies: An evidence‐based practice guideline of the National Society of Genetic CounselorsJournal of Genetic Counseling, 2022
- Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut SyndromeJAMA Neurology, 2022
- The Optimal Target and Connectivity for Deep Brain Stimulation in Lennox–Gastaut SyndromeAnnals of Neurology, 2022
- DBS of Thalamic Centromedian Nucleus for Lennox–Gastaut Syndrome (ESTEL Trial)Annals of Neurology, 2021
- Epilepsy in tuberous sclerosis complex: Findings from the TOSCA StudyEpilepsia Open, 2018
- Common terms for rare epilepsies: Synonyms, associated terms, and links to structured vocabulariesEpilepsia Open, 2018
- Repetitive transcranial magnetic stimulation for the treatment of drug‐resistant epilepsy: A systematic review and individual participant data meta‐analysis of real‐world evidenceEpilepsia Open, 2017
- Lennox-Gastaut syndrome: a comprehensive reviewNeurological Sciences, 2017
- Resective surgery combined with corpus callosotomy for children with non-focal lesional Lennox–Gastaut syndromeActa Neurochirurgica, 2016
- High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on studyEuropean Journal of Pediatrics, 1994